Reprise Biomedical, Inc. is a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology that supports cellular integration. Reprise was created in connection with a spin-off from Miromatrix Medical Inc. in June 2019. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, commercially available medical devices MIROMESH Biologic Matrix and MIRODERM Biologic Wound Matrix as well as all acellular medical devices in development. MIROMESH and MIRODERM are derived via perfusion decellularization of the highly vascularized porcine liver. A non-crosslinked surgical mesh, MIROMESH comes in a variety of sizes suited for hernia repair applications. MIRODERM is indicated for the management of wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds.
Partial Data by Infogroup (c) 2024. All rights reserved.